Summary:
The purpose of the study is to look at the at the impact of an investigational drug called linagliptin on the long-term occurrence of selected complications of cardiovascular disease (e.g. Stroke or heart attack) in people with Type 2 Diabetes Mellitus receiving standard of care.
Qualified Participants Must:
• Be 18 years of age or older
•
Have been diagnosed with type 2 diabetes mellitus
•
Have been receiving a stable dose of anti-diabetic medication for at least 8 weeks or you have not previously received anti-diabetic treatment
•
Have previously had problems with cardiovascular disease and or kidney renal disease
Qualified Participants May Receive:
$50.00 per each completed visit.